Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gefitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 18/20 | 0.98 |
| ▸ | KDR | P35968 | 3/20 | 0.98 |
| ▸ | BRAF | P15056 | 2/20 | 0.98 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.98 |
| ▸ | FLT4 | P35916 | 2/20 | 0.98 |
| ▸ | CIT | O14578 | 1/20 | 0.98 |
| ▸ | GAK | O14976 | 1/20 | 0.98 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.98 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.98 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.98 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.98 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.98 |
| ▸ | STK17B | O94768 | 1/20 | 0.98 |
| ▸ | STK10 | O94804 | 1/20 | 0.98 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.98 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.98 |
| ▸ | ABL1 | P00519 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gefitinib SCHEMBL29371159 | 1.00 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL30887946 | 1.00 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL8208642 | 1.00 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL7866 | 0.99 | EGFR (1.00) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL465143 | 0.99 | EGFR (1.00) | EGFRKDRBRAFEPHB4FLT4 | |
| SCHEMBL1734701 | 0.99 | EGFR (1.00) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL29351046 | 0.99 | EGFR (1.00) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL29351336 | 0.99 | EGFR (1.00) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL2770155 | 0.98 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL28098790 | 0.98 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115433135-B | Gefitinib method for purifying nylon | 山东鲁抗医药股份有限公司 | 2024-10-18 | — | — | CN | claimed |
| CN-116351329-A | Preparation method of lung cancer targeted therapeutic drug and synthesis device thereof | 上海朗泽生物医药科技有限公司 | 2023-06-30 | — | — | CN | claimed |
| US-11478477-B2 | Method for treating cancer by combination of FAK/ALK/ROS1 inhibitor and EGFR inhibitor | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-10-25 | — | — | US | claimed |
| EP-4011376-A2 | COMBINATION OF AN ALK INHIBITOR AND AN EGFR INHIBITOR FOR TREATING CANCER | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2022-06-15 | — | — | EP | claimed |
| CN-113893256-A | Application of compound or pharmaceutically acceptable salt, dimer or trimer thereof in preparation of medicine for treating cancer | 诺未科技（北京）有限公司 | 2022-01-07 | — | — | CN | claimed |
| CN-113893351-A | Composition and application thereof in preparation of medicine for treating cancer | 诺未科技（北京）有限公司 | 2022-01-07 | — | — | CN | claimed |
| US-20210330669-A1 | METHOD FOR TREATING CANCER BY COMBINATION OF FAK/ALK/ROSI INHIBITOR AND EGFR INHIBITOR | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2021-10-28 | — | — | US | claimed |
| EP-3758705-A1 | METHOD FOR TREATING CANCER BY COMBINATION OF FAK/ALK/ROS1 INHIBITOR AND EGFR INHIBITOR | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2021-01-06 | — | — | EP | claimed |
| CN-107098863-B | Preparation method of gefitinib | 重庆莱美隆宇药业有限公司 | 2020-04-10 | — | — | CN | claimed |
| CN-110772638-A | Methods of treating cancer with a combination of a FAK/ALK/ROS1 inhibitor and an EGFR inhibitor | 苏州亚盛药业有限公司 | 2020-02-11 | — | — | CN | claimed |
| WO-2020024825-A1 | METHOD FOR TREATING CANCER BY COMBINATION OF FAK/ALK/ROS1 INHIBITOR AND EGFR INHIBITOR | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2020-02-06 | — | — | WO | claimed |
| CN-107252413-A | A nanometer medicinal sustained-release preparation for treating malignant tumor, and its preparation method | 西南医科大学附属医院 | 2017-10-17 | — | — | CN | claimed |
| CN-102584720-B | Preparation technology o high-purity gefitinib | REYOUNG PHARMACEUTICAL CO LTD | 2014-12-17 | — | — | CN | claimed |
| CN-122094689-A | Combination therapy of diacylglycerol kinase (DGK) alpha inhibitors with other therapies | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4739310-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-05-13 | — | — | EP | disclosed |
| CN-120154720-A | Application of ATP6V1C1 and inhibitor thereof in preparation of medicines for inhibiting lung cancer metastasis or drug resistance | 四川大学华西医院 | 2025-06-17 | — | — | CN | disclosed |
| EP-0823900-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-12-27 | — | — | EP | disclosed |
| US-5770599-A | RECEPTOR TYROSINE KINASE INHIBITORS including 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(2-morpholinoethoxy)quinazoline (gefitinib) | ZENECA LIMITED (GB) | 1998-06-23 | — | — | US | disclosed |
| EP-0823900-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-02-18 | — | — | EP | disclosed |
| WO-1996033980-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210330669-A1 | METHOD FOR TREATING CANCER BY COMBINATION OF FAK/ALK/ROSI INHIBITOR AND EGFR INHIBITOR | ROS1, ALK, PTK2 | EGFR 4/4885KDR 53/4885BRAF 18/4885 |
| US-11478477-B2 | Method for treating cancer by combination of FAK/ALK/ROS1 inhibitor and EGFR inhibitor | ROS1, ALK, PTK2 | EGFR 5/4885KDR 59/4885BRAF 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.